Quotables
"There is practically no chance communications space satellites will be used to provide better telephone, telegraph, television, or radio service inside the United States."
T. Craven, FCC Commissioner ; 1961
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 7906518 | Therapeutic compounds The invention relates to a method of improving oral drug absorption of adenosine analogues by the use of 2′,3′-methylidene acetal adenosine pro-drugs and to the use of these pro-drugs as medicaments. The invention further relates to compounds that are pro-drugs ... | 03/15/2011 |
| 7358235 | Analogs of nitrobenzylthioinosine Analogs or derivatives of nitrobenzylthioinosine compounds. The use of these new analogs of nitrobenzylthioinosine and methods for the treatment of pain and various other indications using these analogs of nitrobenzylthioinosine as well as pharmaceutical composition... | 04/15/2008 |
| 7125993 | Aadenosine receptor antagonists Disclosed are processes for the synthesis of novel compounds that are A2B adenosine receptor antagonists, having the structure of Formula I or Formula II: by cyclizing a compound of the formula (3): | 10/24/2006 |
| 7014851 | Process for inhibiting platelet aggregation An object of the present invention is to provide a platelet aggregation inhibitor without side effects and a supplement food effective for inhibiting platelet aggregation. The platelet aggregation inhibitor has nattokinase as an active ingredient and has Bacillus... | 03/21/2006 |
| 6774130 | Therapeutic compounds for inhibiting interleukin-12 signaling and methods for using same Novel heterocyclic compounds having a six membered ring structure fused to a five membered ring structure are found to be useful for the treatment and prevention of symptoms or manifestations associated with disorders affected by Interleukin-12 (“IL-12”) intrace... | 08/10/2004 |
| 6677316 | Adenosine derivatives and methods of administration A method of treating a patient suffering from or susceptible to ischemic heart disease, peripheral vascular disease or stroke or which subject is suffering pain, a CNS disorder or sleep apnea which comprises administering a therapeutically effective amoun... | 01/13/2004 |
| 6649600 | Adenosine receptor antagonists and methods of making and using the same The invention is based on the discovery that compounds of Formula I are unexpectedly highly potent and selective inhibitors of the adenosine A1 receptor. Adenosine A1 antagonists can be usefull in the prevention and/or treatment of n... | 11/18/2003 |
| 6620796 | Combinatorial library synthesis and pharmaceutically active compounds produced thereby The invention provides new methods for synthesis of nucleotide-based compounds and new libraries of such compounds. Compounds of the invention are useful for a variety of therapeutic applications, including treatment of viral or bacterial infections and a... | 09/16/2003 |
| 6440981 | Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones A method for inhibiting the growth of neoplastic cells by exposure to 2,9-disubstituted purin-6-ones.... | 08/27/2002 |
| 6268372 | Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones A method for inhibiting the growth of neoplastic cells by exposure to 2,9-disubstituted purin-6-ones.... | 07/31/2001 |
| 6124288 | Xanthines and their therapeutic use The subject invention concerns a compound of the formula (i): ##STR1## in which Q represents heteroaryl or heterocyclo optionally substituted with one or more substituents selected from the group consisting of C1-6 alkyl (optionally substi... | 09/26/2000 |
| 6103730 | Amine substituted compounds Compounds and pharmaceutical compositions, including resolved enantiomers and/or diastereomers, hydrates, salts, solvates and mixtures thereof, have the formula: CORE MOIETY--(R)j In these compounds, j is an integer from one to three; the core moiet... | 08/15/2000 |
| 6100271 | Therapeutic compounds containing xanthinyl Therapeutic compounds with at least one carboxylic acid, ester or amide-substituted side chain have the formula: CORE MOIETY --(R)j wherein j is an integer from one to three. The core moiety is non-cyclic or cyclic (carbocyclic or heterocyclic). R m... | 08/08/2000 |
| 6060481 | Method for improving insulin sensitivity using an adenosine receptor antagonist Methods for improving insulin sensitivity in a patient using one or more A2B adenosine receptor antagonists are disclosed. These methods stimulate insulin dependent glucose uptake in muscle.... | 05/09/2000 |
| 5958933 | Neurologically active compounds and compounds with multiple activities A method for treating a mammal having a damaged central nervous system, as the result of trauma or disease, for reestablishing previously destroyed neurological functions in a traumatized or diseased mammal, or for controlling spasticity and for providing... | 09/28/1999 |
| 5861404 | 2,9-disubstituted purin-6-ones 2,9-Disubstituted purin-6-ones are prepared by acylating correspondingly substituted aminoimidazoles in a first step and then cyclizing the product to the purine. The new 2,9-disubstituted purin-6-ones can be employed as active compounds in medicaments, i... | 01/19/1999 |
| 5760042 | Griseolic acid derivatives, their preparation and their use New griseolic acid derivatives have various groups attached to the sugar part in place of the adenine group of griseolic acid itself. These groups are all purine derivatives or ring-opened purine analogs. The compounds are useful as inhibitors of phosphod... | 06/02/1998 |
| 5756511 | Method for treating symptoms of a neurodegenerative condition A method for treating symptoms of Alzheimer's Disease by administering an effective amount of a compound, racemate, isolated R or S enantionmer, solvate, hydrate or salt having the formula: X--terminal heterocyclic moiety. In the above formula, the terminal he... | 05/26/1998 |
| 5714142 | Method and compositions for increasing the serum half-life of pharmacologically active agents by binding to transthyretin-selective ligands Compositions and methods are provided for increasing the serum half-life of a pharmacologically active agent. The novel compositions are covalent conjugates of the selected pharmacologically active agent and a transthyretin-binding ligand such as tetraiio... | 02/03/1998 |
| 5703085 | Xanthine derivatives The present invention relates to novel xanthine derivatives and pharmaceutically acceptable salts thereof, represented by Formula (I): ##STR1## wherein R1, R2, and R3 independently represent hydrogen, lower alkyl, low... | 12/30/1997 |
| 5696124 | Xanthine derivatives with adenosine-antagonistic activity The invention relates to new xanthine derivatives of general formula I, processes for preparing them and their use as pharmaceutical compositions.... | 12/09/1997 |
| 5668139 | A1 adenosine receptor agonists and antagonists Adenosine and xanthine derivatives, and compositions comprising those compounds, are potent selective agonists and antagonists of adenosine receptors. The derivatives and compositions are used to treat conditions, including certain cardiac arrhythmias.... | 09/16/1997 |
| 5641784 | 8-substituted 1,3-dialiphaticxanthine derivatives New xanthine compounds of formula I: ##STR1## wherein the substituents are defined herein, which xanthines are useful as adenosine antagonists.... | 06/24/1997 |
| 5631260 | Xanthine epoxides as A1 adenosine receptor agonists and antagonists Xanthine derivatives, and compositions comprising those compounds, are potent selective antagonists of adenosine receptors. The derivatives and compositions are used to treat conditions, including certain cardiac arrhythmias. The compounds, specifically, ... | 05/20/1997 |
| 5587378 | Therapeutic agent for Parkinson's disease Methods for the treatment of Parkinson's disease comprising administering to a patient an agent which contains, as an active ingredient, a xanthine derivative or a pharmaceutically acceptable salt thereof. The xanthine derivative is represented by the for... | 12/24/1996 |
| 5583137 | Heterocyclic compounds for enhancing antitumor activity 2,6-Diaminopurines, 3,5-diamino-6,7,8,9-tetrahydrobenzo[b]thiophene[2,3-d]pyrimidines and 2,4-diaminothieno[3,2-d]pyrimidines useful as inhibitors of P-glycoproteins and potentiators of chemotherapeutic agents.... | 12/10/1996 |
| 5543415 | Antidepressants The present invention relates to an antidepressant containing as an active ingredient a xanthine derivative or a pharmaceutically acceptable salt thereof, the xanthine derivative being represented by Formula (I) : ##STR1## in which R1, R | 08/06/1996 |
| 5514682 | Fused imidazole and triazole derivatives as 5-HT1 receptor agonists Compounds of formula (I) wherein F represents a Group of the formula (a) ; E represents a bond or a straight or branched alkylene chain containing from 1 to 4 carbon atoms; and the rest of the variables are defined in the specification are selective agoni... | 05/07/1996 |
| 5498819 | Griseolic acid derivatives, their preparation and their use New griseolic acid derivatives have various groups attached to the sugar part in place of the adenine group of griseolic acid itself. These groups are all purine derivatives or ring-opened purine analogs. The compounds are useful as inhibitors of phosphod... | 03/12/1996 |
| 5446046 | A1 adenosine receptor agonists and antagonists as diuretics Adenosine and xanthine derivatives, and compositions comprising those compounds, are potent selective agonists and antagonists of adenosine receptors. The derivatives and composition are used to treat conditions, including certain cardiac arrhythmias.... | 08/29/1995 |
| 5302596 | Tricyclic compounds as TXA2 antagonists Novel tricyclic compound represented by formula ##STR1## possess a TXA2 biosynthesis inhibiting activity and/or a TXA2 receptor antagonizing activity, and are expected to have preventive and therapeutic effects on ischemic disea... | 04/12/1994 |
| 5281605 | Novel xanthine derivatives A compound of formula I ##STR1## wherein R1 is C1-4 alkyl, C3-4 alkenyl or (C3-5 cycloalkyl)-methyl, R2 is C1-4 alkyl, [hydroxy- or (C1-4 alkoxy)-substituted C1-3... | 01/25/1994 |
| 5252598 | Labdane derivatives, a process for their preparation, and their use as medicaments The present invention relates to labdane-derivatives of the formula ##STR1## a process for their preparation and the use of these substances as medicaments, preferably as medicaments having a positive ionotropic effect, an effect of lowering intraocu... | 10/12/1993 |
| 5223504 | Xanthine compounds and compositions, and methods of using them Xanthines of the general formula: ##STR1## wherein R1 represents a straight or branched chain alkyl, alkenyl or alkynyl group of 3-6 carbon atoms, and R2 and R3, which may be the same or different, each represent hydr... | 06/29/1993 |
| 5093331 | Labdane derivatives, a process for their preparation, and their use as medicaments The present invention relates to polyoxygenated labdane-derivatives of the formula ##STR1## a process for their preparation and the use of these substances as medicaments, preferably as medicaments having a positive inotropic effect, an effect o... | 03/03/1992 |
| 5091431 | Phosphodiesterase inhibitors Compounds having an optionally-substituted purine derivative portion and a carbobicyclic or heterobicyclic portion, which compounds are useful as phosphodiesterase inhibitors, are disclosed. Also disclosed are intermediates, methods for making the inhibit... | 02/25/1992 |
| 5063233 | N9 -cyclopentyl-substituted adenine derivatives useful as adenosine receptor agonists The compound of the formula I ##STR1## wherein R, R3 and R5 independently represent hydrogen or hydroxy provided that at least one of R, R3 and R5 represents hydroxy; R1 represents hydrogen, lowe... | 11/05/1991 |
| 4999351 | 7-aryl and heteroaryl ethers of desacetylforskolin Novel forskolin derivatives, intermediates and processes for the preparation thereof, and methods for treating cardiac failure and memory deficit utilizing compounds or compositions thereof are disclosed.... | 03/12/1991 |
| 4971972 | Phosphodiesterase inhibitors having an optionally substituted purine derivative portion and a benzo- or cyclopenta-furan portion Antihypertensive phosphodiesterase inhibitors having an optionally substituted purine derivative portion and a benzo- or cyclopenta-furan derivative portion are disclosed.... | 11/20/1990 |
| 4954504 | N9 -cyclopentyl-substituted adenine derivatives having adenosine-2 receptor stimulating activity The compound of the formula I ##STR1## wherein R, R3 and R5 independently represent hydrogen or hydroxy provided that at least one of R, R3 and R5 represents hydroxy; R1 represents hydrogen, lowe... | 09/04/1990 |
